- Home
- SD vs LYEL Comparison
SD vs LYEL Comparison
Compare SD & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SD | LYEL |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 589.9M | 490.1M |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SD | LYEL |
|---|---|---|
| Price | $16.63 | $19.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $27.25 |
| AVG Volume (30 Days) | ★ 330.6K | 98.1K |
| Earning Date | 03-04-2026 | 03-12-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | ★ 12.43 | N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $12.65 | N/A |
| Revenue Next Year | $1.75 | N/A |
| P/E Ratio | $8.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.81 | $0.39 |
| 52 Week High | $18.45 | $45.00 |
Technical Indicators
Market Signals| Indicator | SD | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 35.81 |
| Support Level | $16.19 | $15.82 |
| Resistance Level | $18.16 | $27.30 |
| Average True Range (ATR) | 0.68 | 2.04 |
| MACD | -0.15 | -0.39 |
| Stochastic Oscillator | 26.64 | 7.97 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.